Prostate-specific antigen (PSA) is a protein produced by the prostate gland. Elevated levels in the blood may signal prostate inflammation, enlargement, or cancer, though many noncancerous conditions also raise PSA. Levels above 4.0 ng/mL often prompt further testing.
PSA is measured through a simple blood test. Normal values typically fall below 4.0 nanograms per milliliter, though thresholds vary slightly by lab and age group. Levels between 4.0 and 10.0 are considered mildly elevated and may warrant monitoring. Values above 10.0 suggest a higher risk of prostate cancer and usually lead to biopsy recommendations.
The U.S. Preventive Services Task Force (USPSTF) notes that PSA screening remains controversial due to risks of overdiagnosis and overtreatment. However, for men aged 50 and older, or those with a family history of prostate cancer, regular screening helps detect aggressive disease early. The American Cancer Society recommends discussing PSA testing with a doctor starting at age 50, or earlier for Black men and those with a family history.
Benign prostatic hyperplasia (BPH), or enlarged prostate, is the most frequent reason for increased PSA. As men age, the prostate naturally grows. This growth can compress the urethra and irritate prostate tissue, leading to higher PSA release into the bloodstream. Studies show that nearly half of men over 60 have BPH-related PSA elevation.
Prostatitis, or inflammation of the prostate, also raises PSA. Acute bacterial prostatitis causes fever, pelvic pain, and urinary urgency. Chronic prostatitis may present with persistent discomfort and elevated PSA without infection. A 2021 study in European Urology found that men with chronic prostatitis had average PSA levels 2.5 times higher than controls.
Recent sexual activity within 48 hours of testing can temporarily spike PSA by up to 30%. The mechanism involves mechanical stimulation of the prostate during ejaculation, which increases fluid secretion and leakage into the bloodstream. Men scheduled for PSA tests are advised to abstain from sex for two days prior.
Transrectal ultrasound (TRUS) and prostate biopsies improve PSA. After a biopsy, levels can rise by 50% or more and remain high for several weeks. The American Urological Association advises waiting at least four weeks after a biopsy before repeating a PSA test to avoid false positives.
Urinary catheterization, especially in men with bladder outlet obstruction, can trigger PSA release. A 2019 retrospective analysis in JAMA Internal Medicine showed that catheter insertion raised median PSA by 1.8 ng/mL in hospitalized patients. This effect is transient but must be considered when interpreting results.
Physical trauma to the pelvic area, such as bicycle riding or rectal exams, may also contribute. A 2020 study in Urology reported that men who rode bicycles for over 100 miles per week had a 12% higher average PSA than non-riders. The pressure from the saddle may affect prostate perfusion and cellular shedding.
Prostate cancer itself is a major cause of elevated PSA. However, not all high levels indicate cancer. In a large cohort study published in The Lancet Oncology, only 15% of men with PSA levels between 4.0 and 10.0 were diagnosed with prostate cancer after biopsy. The rest had BPH or prostatitis.
Some medications can influence PSA. Finasteride (Propecia), used to treat male pattern baldness and BPH, reduces PSA by about 50% by shrinking prostate volume. Men taking finasteride must have their PSA values doubled to interpret results accurately. Conversely, testosterone therapy may increase PSA in some users, though evidence is mixed.
Age and race play roles. PSA tends to rise gradually with age. The average level for men aged 50-59 is 1.5 ng/mL; for 60-69, it's 2.5 ng/mL. Black men have higher baseline PSA levels and are more likely to develop aggressive prostate cancer. The National Institutes of Health reports that Black men are 70% more likely to be diagnosed with advanced-stage disease compared to White men.
Many assume high PSA equals cancer. This is incorrect. A single elevated result doesn't confirm malignancy. The PSA velocity-the rate of change over time-is more predictive than a single value. A rise of more than 0.35 ng/mL per year suggests higher risk and warrants investigation.
PSA density, calculated as PSA divided by prostate volume (from MRI or ultrasound), improves specificity. A density above 0.15 ng/mL per cm³ increases the likelihood of clinically significant cancer. This metric helps reduce unnecessary biopsies in men with large prostates and moderately elevated PSA.
A 62-year-old man presents with a PSA of 6.8 ng/mL. He has no symptoms of urinary retention or pain. His digital rectal exam is normal. He recently completed a 10-day course of antibiotics for a urinary tract infection and rode his bike 50 miles last weekend.
His urologist orders a repeat PSA test after four weeks. The follow-up shows 5.1 ng/mL. A free PSA test reveals 0.9 ng/mL, giving a percent-free PSA of 17.3%. Since this is below 25%, the risk of cancer is moderate. An MRI of the prostate shows no suspicious lesions. The patient undergoes a targeted biopsy, which detects low-grade cancer (Gleason 3+3=6).
This case illustrates that multiple factors-recent infection, physical activity, and age-can influence PSA. The decision to biopsy relied on free PSA and imaging, not the absolute value alone.
Men with PSA levels above 10.0 ng/mL should undergo biopsy unless contraindicated. Those with levels between 4.0 and 10.0 and abnormal DRE findings need immediate evaluation. Even without symptoms, a rising trend over time demands attention.
Men with a family history of prostate cancer should consider screening at age 45. African American men are encouraged to start at age 40. If a man has a first-degree relative with prostate cancer, his lifetime risk doubles. Early detection improves survival rates-99% of men diagnosed with localized disease survive five years.
PSA is a tool-not a diagnosis. Its value lies in tracking changes over time, combined with clinical findings. No single test defines prostate health. Regular discussion with a healthcare provider ensures accurate interpretation and appropriate action.